Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier:
NCT00923884
First received: June 17, 2009
Last updated: November 11, 2014
Last verified: July 2014

June 17, 2009
November 11, 2014
March 2009
Not Provided
Evaluation of the association between polymorphisms in the enzymes ABCB1, CYP1B1, and CYP19 and clinical outcomes, with overall survival of greatest interest, in patients undergoing treatment for lung cancer. [ Time Frame: Death or the conclusion of a 5-year follow-up period ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00923884 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

Background:

  • The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer.

Objectives:

  • To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer.
  • To establish a repository of genetic information for future studies of these differences and their relation to lung cancer.

Eligibility:

  • Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute.

Design:

  • After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential.
  • Approximately half a tablespoon of blood will be drawn.
  • Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study
  • Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.

Background:

  • Lung cancer is the leading cause of cancer deaths among men and women worldwide.
  • Despite modern surgical, radiation, and chemotherapeutic interventions, the prognosis for patients with lung cancer remains poor, with an overall cure rate of less than 15%.
  • Genetic polymorphisms in drug-metabolizing enzymes, transporters, growth factor and hormonal receptors, DNA repair enzymes, and transcription factors might affect an individual s response to chemotherapy and radiation.
  • Interindividual differences in efficacy and toxicity of cancer chemotherapy and radiation are especially important given the narrow therapeutic index of these modalities.
  • Many of these differences have not been extensively explored in patients with lung cancer.

Objectives:

  • To better understand the genotype-phenotype relationship between genetic polymorphisms and clinical outcomes, with a focus on overall survival, following lung cancer therapy.
  • To better understand differences in outcome between Caucasian and African American patients being treated for lung cancer as a function of genotype.
  • To establish a DNA repository for the investigation of polymorphisms related to outcomes in lung cancer.
  • To develop methodology for the isolation, enumeration and live cell culture of circulating tumor cells (CTC) from lung cancer patients with microfiltration devices.

Eligibility:

- All individuals with the diagnosis of lung cancer being treated at the Washington D.C. Veteran s Affairs Hospital, Washington Hospital Center (WHC) or the Medical Oncology Branch of the National Cancer Institute (NCI).

Design:

  • A single 7-ml sample of venous blood will be obtained from all patients enrolled onto this study, for isolation of DNA.
  • Two 5 ml samples of venous blood, drawn immediately following the 7 ml sample, will be obtained from all patients enrolled on this study at the NCI Clinical Center (only), for CTC studies.
  • Polymorphisms in the following genes: ABCB1, ABCG2, COMT, CYP17, CYP19, CYP1B1, CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2J2, CYP3A4, CYP3A5, DPYD, EPHX2, ERalpha, ERbeta, ERCC1, ERCC2, GSTP1, HIF1A, MPO, MTHFR, NQO1, p53, PPARD, SLCO1B3, TYMS, UGT1A1, VEGF, VEGFR, EGFR, SLC28A1, CDA, XRCC1, OCT1, and OCT2 will be analyzed by the Clinical Pharmacology Program.
  • Methodology for the isolation, enumeration, and live cell culture of CTC with microfiltration devices will be developed by the NCI Genetics Branch.
  • Patients will be followed at the medical oncology clinic at the Washington DC VA Hospital, WHC, or the NCI and the following information will be recorded in a confidential database: age, gender, race/ethnicity, smoking history, histology, stage, treatment(s) received, response, toxicity (grades 3-5), time to disease progression, time to death.
  • Associations between genetic polymorphisms and response to therapy, toxicity and clinical outcomes will be analyzed.
  • The results of the CTC studies will be applied to the initial development and clinical

validation of CTC technology and lung cancer assays.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Small-Cell Lung
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
442
Not Provided
Not Provided
  • INCLUSION CRITERIA:

    1. Patients 18 years of age and older are eligible.
    2. Histologic diagnosis of primary lung carcinoma. For non small cell lung cancer, patients can be stage I to IV, and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy). For small cell lung cancer, patients can be limited or extensive stage and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy).
    3. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol.
    4. Patients with a current diagnosis of or a prior history of other cancers may be included onto this protocol.
    5. Patients may have either normal organ function or impaired organ function.

EXCLUSION CRITERIA:

1. Children will not be eligible.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00923884
090103, 09-C-0103
Not Provided
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Arun Rajan, M.D. National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP